1. Home
  2. TPVG vs IPHA Comparison

TPVG vs IPHA Comparison

Compare TPVG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriplePoint Venture Growth BDC Corp.

TPVG

TriplePoint Venture Growth BDC Corp.

HOLD

Current Price

$4.72

Market Cap

224.9M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.82

Market Cap

189.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TPVG
IPHA
Founded
2013
1999
Country
United States
France
Employees
N/A
163
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.9M
189.5M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
TPVG
IPHA
Price
$4.72
$1.82
Analyst Decision
Hold
Strong Buy
Analyst Count
5
4
Target Price
$5.90
$5.75
AVG Volume (30 Days)
271.6K
14.5K
Earning Date
05-06-2026
03-26-2026
Dividend Yield
17.66%
N/A
EPS Growth
N/A
N/A
EPS
0.23
N/A
Revenue
N/A
N/A
Revenue This Year
$7.67
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
$20.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.48
$1.18
52 Week High
$7.50
$2.63

Technical Indicators

Market Signals
Indicator
TPVG
IPHA
Relative Strength Index (RSI) 28.71 56.03
Support Level $4.48 $1.73
Resistance Level $5.70 $1.90
Average True Range (ATR) 0.17 0.08
MACD -0.09 -0.00
Stochastic Oscillator 9.30 56.59

Price Performance

Historical Comparison
TPVG
IPHA

About TPVG TriplePoint Venture Growth BDC Corp.

TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: